Levofloxacin hemihydrate

Levofloxacin hemihydrate - Names and Identifiers

Name	(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1)
Synonyms	Levofloxacine LEVOFLOXACIN HCL (S)-(-)-Ofloxacine levofloxacin hydrate Levofloacin Impurity 16 Levofloxacin hemihydrate LEVOFLOXACINH HYDROCHLORIDE (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hydrate (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hydrochloride
CAS	138199-71-0
EINECS	604-067-2
InChI	InChI=1/2C18H20FN3O4.H2O/c21-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h27-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1

Levofloxacin hemihydrate - Physico-chemical Properties

Molecular Formula	C18H22FN3O5
Molar Mass	379.39
Melting Point	214-216°C
Boling Point	571.5°C at 760 mmHg
Flash Point	299.4°C
Solubility	Aqueous Base (Slightly), DMSO (Sparingly), Methanol (Slightly)
Vapor Presure	6.7E-14mmHg at 25°C
Appearance	neat
Color	Pale Yellow to Light Yellow
Storage Condition	Sealed in dry,2-8°C
Use	This product is for scientific research only and shall not be used for other purposes.

Levofloxacin hemihydrate - Risk and Safety

Hazard Symbols	N - Dangerous for the environment
Risk Codes	50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
Safety Description	S24/25 - Avoid contact with skin and eyes. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. S60 - This material and its container must be disposed of as hazardous waste.
WGK Germany	3
HS Code	2934990002

Levofloxacin hemihydrate - Nature

Open Data Verified Data

light yellow crystalline powder, odorless, bitter. Levofloxacin is The levorotatory form of ofloxacin, a hemihydrate, and its solubility in water is 10 times that of the latter. Needle-like crystals were obtained from ethanol-diethyl ether with a melting point of 225-227 °c.

Last Update：2024-01-02 23:10:35

Levofloxacin hemihydrate - Preparation Method

Open Data Verified Data

The racemic ofloxacin can be directly separated by high performance liquid chromatography column filled with special stationary phase; Or the ofloxacin is treated with hydroxylamine sulfate and acidified with hydrochloric acid to obtain hydrochloride, after treatment with a basic ion exchange column, the obtained amphoteric compound is added with (S)-()-mandelic acid, which forms crystals after salt formation with (a)-isomer, and can be passed through an ion exchange resin, the product was obtained by reductive deamination. Or 2-(ethoxymethylene) -3-oxo-3-(2,3,4,5 A tetrafluorophenyl) propionic acid ethyl ester, and then with (S) a 2 amino propanol reaction introduced asymmetric carbon atoms, by ring closure, hydrolysis, the introduction of methyl piperazine. It can also be 2,3-= fluoro-6-nitrophenol as raw materials, and R configuration of glycidyl tosylate in the presence of phase transfer catalyst reaction to produce optically active compounds, it is obtained by reduction and condensation with diethyl ethoxymethylene malonate (EMME), and finally by reagent treatment, ring closure, hydrolysis and introduction of piperazine group.

Last Update：2022-01-01 09:09:01

Levofloxacin hemihydrate - Use

Open Data Verified Data

Japan first Pharmaceutical Co., Ltd., launched in 1993. Levofloxacin has excellent in vitro activity, less toxic side effects, greater safety and good pharmacokinetic properties than ofloxacin. Can be widely used in respiratory tract infection, gynecological disease infection, skin and soft tissue infection, surgical infection, biliary tract infection, A broad-spectrum fluoroquinolone antibacterial drug for oral or parenteral use in a variety of bacterial infections such as sexually transmitted diseases and ear, nose and mouth infections.

Last Update：2022-01-01 09:09:01